CancerIQ key facts
as of Oct 2026- Developer of a precision health technology designed for doctors to identify and manage patients at high risk for cancer.
- CancerIQ is valued at approximately $50.0M as of Oct 2026 (last reported valuation).
- It has raised $30.8M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Matter (Consulting Services (B2B)), Lightbank (Venture Capital), MSD Global Health Innovation Fund, HealthX Ventures, Impact Engine — 26 tracked in total.
- Status: Privately Held (backing).
CancerIQ's last reported valuation, Mar 2022. Nothing priced has surfaced since.
- ·The complete investor list: 26 names
- ·Watch CancerIQ: the Monday email on marks, rounds and moves
CancerIQ funding rounds
No funding rounds for CancerIQ are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs CancerIQ
26+CancerIQ valuation
CancerIQ's last reported valuation was $50 million in Mar 2022. No priced round, secondary trade or fund mark has surfaced since.
CancerIQ investors
26 investors are on record for CancerIQ, including Matter (Consulting Services (B2B)), Lightbank (Venture Capital), MSD Global Health Innovation Fund and HealthX Ventures.
About CancerIQ
Developer of a precision health technology designed for doctors to identify and manage patients at high risk for cancer. The company's platform offers predictive analytics and screening tools to identify at-risk patients, clinical guidance with proven outcomes, a digital genetic test ordering platform, and patient management and education tools, enabling clinicians to save time, reduce the cost of care, and improve outcomes by detecting cancer at an early stage.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2013
- Employees
- 34
- Website
- canceriq.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.